8-K: Supernus Q3 Revenue Up 9%, Raises 2025 Outlook

Supernus Pharmaceuticals reported a 9% increase in Q3 2025 total revenues to $192.1 million, driven by strong growth products, and raised its full-year 2025 revenue guidance.

Summary

• Total revenues increased 9% to $192.1 million in the third quarter of 2025 compared to the same period in 2024.
• Combined revenues from the company's four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) surged 52% to $149.2 million in Q3 2025.
• Qelbree net sales rose 31% to $81.4 million, with total IQVIA prescriptions increasing 23% compared to Q3 2024.
• GOCOVRI net sales increased 15% to $40.8 million in Q3 2025.
• ONAPGO generated net product sales of $6.8 million in its first full quarter following its U.S. commercial launch in April 2025.
• Collaboration revenue from ZURZUVAE was $20.2 million in Q3 2025, representing approximately two months of revenue post-Sage acquisition.
• GAAP operating loss was $60.2 million in Q3 2025, compared to operating earnings of $40.9 million in Q3 2024, primarily due to higher selling, general and administrative expenses, including approximately $70.0 million in acquisition-related costs from the Sage acquisition.
• Adjusted operating earnings (non-GAAP) were $41.9 million in Q3 2025, down from $67.7 million in Q3 2024.
• Net loss was $45.1 million, or $0.80 diluted loss per share, in Q3 2025, compared to net earnings of $38.5 million, or $0.69 diluted earnings per share, in Q3 2024.
• Cash, cash equivalents, and current marketable securities were approximately $281.2 million at September 30, 2025, a decrease from $453.6 million as of December 31, 2024, primarily due to funding the Sage acquisition.
• Full-year 2025 total revenue guidance was increased to $685 million $705 million from previous guidance of $670 million $700 million.
• Full-year 2025 adjusted operating earnings (non-GAAP) guidance was increased to $125 million $145 million from previous guidance of $105 million $135 million.

Sentiment

Score: 7

Explanation: The company demonstrated strong growth in its key products and raised its full-year guidance, indicating positive operational momentum. However, the GAAP operating loss, decrease in cash due to the acquisition, and the critical supply constraint for ONAPGO introduce notable concerns and risks that temper overall sentiment.

Positives

• Combined revenues from the four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) increased 52% to $149.2 million in Q3 2025 compared to Q3 2024.
• Total revenues increased 9% to $192.1 million in Q3 2025 compared to the same period in 2024.
• Qelbree net sales grew 31% to $81.4 million in Q3 2025, with total IQVIA prescriptions increasing 23% year-over-year.
• GOCOVRI net sales increased 15% to $40.8 million in Q3 2025, driven by growth in prescriptions and prescribers.
• ONAPGO generated $6.8 million in net product sales in its first full quarter following U.S. commercial launch in April 2025, with over 1,300 enrollment forms submitted by over 450 prescribers.
• Collaboration revenue from ZURZUVAE was $20.2 million in Q3 2025, with U.S. sales increasing approximately 150% compared to Q3 2024 and 19% compared to Q2 2025.
• Completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025.
• Increased full-year 2025 total revenue guidance to $685 million $705 million (from $670 million $700 million).
• Increased full-year 2025 adjusted operating earnings (non-GAAP) guidance to $125 million $145 million (from $105 million $135 million).

Negatives

• GAAP operating loss was $60.2 million in Q3 2025, compared to operating earnings of $40.9 million in Q3 2024, primarily due to higher selling, general and administrative expenses including $70.0 million in acquisition-related costs.
• Net loss was $45.1 million, or $0.80 diluted loss per share, in Q3 2025, compared to net earnings of $38.5 million, or $0.69 diluted earnings per share, in Q3 2024.
• Cash, cash equivalents, and current marketable securities decreased to $281.2 million at September 30, 2025, from $453.6 million at December 31, 2024, primarily due to funding the Sage acquisition.
• Net sales of older products declined significantly in Q3 2025: APOKYN by 48% to $10.4 million, Trokendi XR by 35% to $10.0 million, and Oxtellar XR by 59% to $12.1 million.
• Total net product sales decreased 1% to $168.5 million in Q3 2025 compared to Q3 2024.

Risks

• Supplier constraints are impacting the company's ability to fully meet the stronger than expected demand for ONAPGO, requiring prioritization for current patients and pausing new patient initiations.
• Continued generic erosion of Trokendi XR and Oxtellar XR, which are not expected to constitute a significant part of future revenue.
• The company's ability to sustain and increase its profitability.
• The company's ability to raise sufficient capital to fully implement its corporate strategy.
• Risks associated with commercializing products, including those acquired through the Sage acquisition.
• Uncertainty regarding the timing and progress of clinical trials for product candidates (SPN-817, SPN-820, SPN-443) and projected expenditures.
• The company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize product candidates.
• The company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others.
• The impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs.

Future Outlook

The company is increasing its full-year 2025 total revenue guidance to $685 million $705 million and adjusted operating earnings guidance to $125 million $145 million, reflecting strong performance in the first nine months of 2025. The focus for the remainder of 2025 and into 2026 will be on the performance of its four growth products and overall operating efficiency. In its pipeline, the Phase 2b study for SPN-817 (epilepsy) is ongoing, a follow-on Phase 2b trial for SPN-820 (depression) is expected to initiate by the end of 2025, and a Phase 1 study for SPN-443 (ADHD) is expected to initiate in 2026. The company is actively working to resolve ONAPGO supply constraints to resume new patient initiations as soon as possible.

Management Comments

• "Our strong operating results continued into the third quarter of 2025, reflecting continued momentum from Qelbree and GOCOVRI, collaboration revenue from ZURZUVAE, and an encouraging start to the launch of ONAPGO."
• "Our focus for the remainder of the year and into 2026 will be on the performance of our four growth products and the high-level operating performance across the business to deliver sustained growth and long-term value for shareholders."

Industry Context

Supernus operates in the central nervous system (CNS) disease market, with products addressing ADHD, Parkinson's disease, postpartum depression, and epilepsy. The strong growth of Qelbree (ADHD) and GOCOVRI (Parkinson's dyskinesia) indicates robust demand in these therapeutic areas. The successful integration of ZURZUVAE (postpartum depression) through the Sage acquisition positions the company in a new, high-growth segment. However, the significant decline in older products like Trokendi XR and Oxtellar XR highlights the ongoing challenge of generic competition in the pharmaceutical industry, necessitating continuous innovation and successful new product launches to maintain revenue growth. The ONAPGO supply constraint underscores the complexities of pharmaceutical manufacturing and supply chain management, even for high-demand novel therapies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. Therefore, a direct comparison to industry standards with specific details is not possible based solely on the provided information.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through growth products and pipeline, but short-term concerns due to GAAP losses, acquisition costs, and ONAPGO supply issues. Increased guidance is positive.
• Patients (ONAPGO): Patients currently on ONAPGO are prioritized, but new patients face delays in accessing the treatment due to supply constraints.
• Employees: Integration of Sage Therapeutics employees following the acquisition.
• Suppliers: The ONAPGO supply constraint highlights the critical role of suppliers and the need for robust supply chain management.

Next Steps

• Build adequate inventory and resume new patient initiations for ONAPGO as soon as possible.
• Provide timely updates on progress in resolving the ONAPGO supply constraint.
• Initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial for SPN-820 by the end of 2025.
• Initiate a Phase 1 single-ascending/multiple-ascending dose study for SPN-443 in adult healthy volunteers in 2026.
• Host a conference call and webcast on November 4, 2025, at 4:30 p.m. Eastern Time to discuss results.

Key Dates

Recommendation

While Supernus shows strong growth in its core products and has raised its full-year guidance, the significant GAAP operating loss, the substantial cash outflow for the Sage acquisition, and critically, the supply constraint impacting ONAPGO's launch momentum present a mixed picture. The ONAPGO issue, if prolonged, could significantly impact future revenue and market perception. Investors should hold to monitor the resolution of the supply chain issues and the company's ability to translate strong product demand into sustained profitability, especially given the ongoing generic erosion of older products.

Keywords

Supernus, SUPN, Pharmaceuticals, CNS diseases, Q3 2025, Financial Results, Earnings, Revenue, Qelbree, GOCOVRI, ONAPGO, ZURZUVAE, Sage acquisition, Parkinson's disease, ADHD, Depression, Epilepsy, Supply chain, Guidance